Cellular Biomedicine’s ReJoin for Knee OA Accepted for Trial in China

Cellular Biomedicine's drug application for ReJoin® therapy for knee osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China.

ReJoin is an off-the-shelf autologous mesenchymal progenitor cell therapy, developed completely in-house. It comprises adipose tissue obtained from the patient that is expanded using a serum- and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us